EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials

G Martini iD, D Ciardiello iD, V Famiglietti, D Rossini, C Antoniotti, T Troiani, S Napolitano, L Esposito, T P Latiano, E Maiello, M Del Re, S Lonardi und 10 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.5699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von G Martini und 21 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "L. Vanvitelli", Naples, Italy. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rechallenge strategy is based on the concept that a subset of patients with RAS wild‐type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti‐EGFR based‐therapy. We performed a pooled analysis of two‐phase II prospective trials to determine the role of rechallenge in third‐line mCRC patients with RAS/BRAF WT baseline circulating tumor DNA (ctDNA). Individual data of 33 and 13 patients from CAVE and CRICKET trials that received as third‐line therapy cetuximab rechallenge were collected. Overall survival (OS), Progression‐free survival (PFS), Overall response rate (ORR), Stable disease (SD) >6 months were calculated. Adverse events were reported. For the whole 46 patient population, median PFS (mPFS) was 3.9 months (95% Confidence Interval, CI 3.0–4.9) with median OS (mOS) of 16.9 months (95% CI 11.7–22.1). For CRICKET patients, mPFS was 3.9 months (95% CI 1.7–6.2); mOS was 13.1 months (95% CI 7.3–18.9) with OS rates at 12, 18, and 24 months of 62%, 23%, and 0%, respectively. For CAVE patients, mPFS was 4.1 months (95% CI 3.0–5.2); mOS was 18.6 months (95% CI 11.7–25.4) with OS rates at 12, 18, 24 months of 61%, 52%, 21%, respectively. Skin rash was more frequently reported in CAVE trial (87.9% vs. 30.8%; p = 0.001), whereas a increased incidence of hematological toxicities was observed in CRICKET trial (53.8%% vs. 12.1%; p = 0.003). Third‐line cetuximab rechallenge in combination with either irinotecan or avelumab in RAS/BRAF WT ctDNA mCRC patients represents a promising therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAColorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansCetuximabIrinotecanProto-Oncogene Proteins B-rafProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene Proteins p21(ras)Antibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

cetuximabimmunotherapymetastatic colorectal cancerrechallenge

Substanzen

CetuximabIrinotecanProto-Oncogene Proteins B-rafCirculating Tumor DNAProto-Oncogene Proteins p21(ras)avelumabAntibodies, Monoclonal, HumanizedBRAF protein, human

Autor:innen und Institutionen

  • Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "L. Vanvitelli", Naples, Italy.
  • Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Medical Oncology, Azienda Ospedaliero-Universitaria, Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Oncologia Medica, Ospedale Casa Sollievo della Sofferenza-IRCCS foundation, San Giovanni Rotondo, Italy.
  • Medical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Department of Oncology, San Bortolo General Hospital, Vicenza, Italy.

ORCID-Profile: G Martini, D Ciardiello, F Pietrantonio, E Martinelli

Zitieren

APA

Martini, G., Ciardiello, D., Famiglietti, V., Rossini, D., Antoniotti, C., Troiani, T., Napolitano, S., Esposito, L., Latiano, T. P., Maiello, E., Del Re, M., Lonardi, S., Aprile, G., Santini, D., Masi, G., Avallone, A., Normanno, N., Pietrantonio, F., Pinto, C., …, & Martinelli, E. (2023). Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials. Cancer Medicine. https://doi.org/10.1002/cam4.5699

Vancouver

Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, et al. Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials. Cancer Medicine. 2023. doi:10.1002/cam4.5699

BibTeX
@article{Martini2023,
  author = {Martini, G and Ciardiello, D and Famiglietti, V and Rossini, D and Antoniotti, C and Troiani, T and Napolitano, S and Esposito, L and Latiano, T P and Maiello, E and Del Re, M and Lonardi, S and Aprile, G and Santini, D and Masi, G and Avallone, A and Normanno, N and Pietrantonio, F and Pinto, C and Ciardiello, F and Cremolini, C and Martinelli, E},
  title = {Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5699}
}
Kostenlos starten →